Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Development of Resistance Mutations in Pregnant HIV-Positive (+) Women Following Perinatal Antiretroviral Therapy in Israel

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by Hadassah Medical Organization.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00197366
First received: September 14, 2005
Last updated: June 11, 2007
Last verified: September 2005

September 14, 2005
June 11, 2007
March 2005
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00197366 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Development of Resistance Mutations in Pregnant HIV-Positive (+) Women Following Perinatal Antiretroviral Therapy in Israel
Development of Resistance Mutations in the Human Immunodeficiency Virus (HIV) in Pregnant HIV+ Women Receiving Perinatal Antiretroviral Therapy in Israel

It has been shown that treatment of HIV-positive women with antiretroviral medication during pregnancy reduces the risk of HIV transmission to the child. However, such treatment could lead to the selection of resistant virus strains in the mother. The object of this study is to check HIV+ pregnant women for resistance mutations in HIV before and after the antiretroviral therapy they receive during pregnancy. HIV-positive newborns will also be tested, to see if a resistant virus strain was transmitted from mother to child.

The project will be performed in collaboration with the Israeli National HIV Reference Center Laboratory, which maintains a national bank of HIV-positive blood samples, and with HIV/AIDS treatment centers located throughout Israel.

An initial survey will identify retrospectively those HIV+ women who were given antiretroviral therapy while pregnant and stopped treatment after delivery. The list of HIV+ deliveries over the past five years in each participating hospital will be reviewed, and all HIV-positive women who received antiretroviral treatment during pregnancy will be invited to participate in the study project. Women who are currently pregnant, or become pregnant during the study, will be invited to participate when pregnancy is diagnosed. After obtaining informed consent, two blood samples will be obtained: one before the initiation of perinatal treatment, and the other following delivery. (Due to technical limitations, only samples with viral loads above 1000 cp/ml can be genotyped. It is expected that HIV loads will rise following cessation of antiretroviral treatment, and that almost all samples will be eligible for resistance testing.)

In addition, after obtaining maternal informed consent, samples from newborns infected perinatally with HIV will also be tested for resistance mutations, and these will be compared with the resistance pattern found in the mother.

The samples obtained will be tested for genotypic resistance mutations. The results will be transmitted to the treating physician to assist in choice of antiretroviral therapy for the women and their children, if needed. The data will also be used to establish a national database to evaluate and improve existing protocols for perinatal antiretroviral treatment, and will be used to contribute to international databases of HIV resistance. All resistance data, except that given to the health care provider(s), will be transmitted without additional identifying information.

Observational
Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Not Provided
Not Provided
Not Provided
Not Provided
HIV Infections
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
50
December 2007
Not Provided

Inclusion Criteria:

  1. HIV-positive women currently pregnant or with a past pregnancy in Israel
  2. Blood/plasma samples available before and/or after perinatal antiretroviral treatment (before or during pregnancy if not treated)
  3. HIV viral load in the samples adequate for resistance testing (approximately 1000 copies/ml)
  4. Informed consent obtained

Exclusion Criteria:

  1. Samples not available or inadequate viral load
  2. Informed consent not obtained
Female
18 Years and older
No
Contact: Shlomo Maayan, Professor 972-2-6776539 shlomo_m@hadassah.org.il
Contact: Rebekah Karplus, MD 972-50-857-3436 reba_k@netvision.net.il
Israel
 
NCT00197366
16-25.02.05-HMO-CTIL
Not Provided
Not Provided
Hadassah Medical Organization
Not Provided
Principal Investigator: Shlomo Maayan, MD Hadassah-Hebrew U Medical Center
Principal Investigator: Zehava Grossman, PhD Central Virology Laboratory Tel HaShomer
Principal Investigator: Rebekah Karplus, MD Hadassah-Hebrew U Medical Center
Hadassah Medical Organization
September 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP